TABLE 2.
List of MAbs generated against SEB toxins
| Source | Ab(s) | Affinity unit(s) |
In vitro model(s) | In vivo model(s) |
Reference |
|---|---|---|---|---|---|
| Murine | lFD7, 2DA3 and 2HA10, 2EG5 and 2GD9 | BALB/c splenocytes | 72 | ||
| Murine | B334, B327, B87, 2B33 | nM | Mouse Vβ8.2 + T cell (KS-6.1) | 64 | |
| Murine | MAb5 (anti-TSST MAb) | Human PBMCs | 63 | ||
| Chicken | IgY | BALB/c | Rhesus monkeys |
66 | |
| Murine phage display | Soluble SEB-ScFv | nM | 73 | ||
| Chimeric | Ch82M and Ch63 | pM | HLA-DR3 mouse splenocytes | 67 | |
| Human | 10 Fab and 4 full-length MAbs | nM | Human PBMCs | BALB/c | 69 |
| Human | Human MAb79G9, human MAb154 | pM–nM | Human PBMCs | BALB/c | 70 |
| Murine | 20B1, 14G8, 6D3, 4C7 | Human T cells | BALB/c, HLA-DR3 |
21 | |
| Chimeric + lovastatin | Ch82M and Ch63 with lovastatin | BALB/c mouse splenocytes | HLA-DR3 | 68 | |
| Murine | 3F3 (anti-SEAand -SEB) | 74 | |||
| Synthetic human MAb | IgG 075, IgG 079, IgG 079-P, IgG 119, IgG 120, IgG 121 |
nM | Human PBMCs | BALB/c | 71 |